Revlimid vs Stelara
Side-by-side drug price comparison from Medicare Part D data
Verdict
Stelara costs 39% less per claim than Revlimid ($7763.00 vs $12786.00). Stelara has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Stelara at $5.6B.
| Metric | Revlimid | Stelara |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $12,786 | $7,763* |
| Total Medicare Spending Total Medicare Part D spending on this drug | $7.8B | $5.6B |
| Total Claims | 612,000 | 720,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | -3.4%* | 6.3% |
| Generic Available | No | Yes |
| Condition | Cancer | Autoimmune Diseases |
| Total Beneficiaries | 58,000 | 114,000 |
Stelara costs 39% less per claim than Revlimid ($7763.00 vs $12786.00). Stelara has a generic alternative available. Total Medicare spending: Revlimid at $7.8B vs Stelara at $5.6B.
Explore More
Comparing Revlimid and Stelara on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
Practical use of the comparison: read the data above, then drill into the individual Revlimid and Stelara detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.